No­var­tis sues over IRA ahead of En­tresto price ne­go­ti­a­tions

No­var­tis is the lat­est drug­mak­er to sue the fed­er­al gov­ern­ment over the In­fla­tion Re­duc­tion Act af­ter learn­ing its block­buster heart drug En­tresto will be up for the first round of Medicare price ne­go­ti­a­tions in 2026.

Un­der the IRA, drug­mak­ers will be re­quired to par­tic­i­pate in Medicare price ne­go­ti­a­tions or else pay a steep fine or risk los­ing Medicare and Med­ic­aid cov­er­age al­to­geth­er. No­var­tis joins a hand­ful of phar­ma com­pa­nies ar­gu­ing the new leg­is­la­tion is un­con­sti­tu­tion­al and could sti­fle in­no­va­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER